ProQR Therapeutics (NASDAQ:PRQR) Lowered to “Hold” at Zacks Investment Research

ProQR Therapeutics (NASDAQ:PRQRGet Rating) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report issued on Thursday, Zacks.com reports.

According to Zacks, “ProQR Therapeutics B.V. is a biotech company. It is engaged in the discovery and development of RNA-based therapeutics for the treatment of severe genetic disorders, with an initial focus on Cystic Fibrosis (CF). The Company’s lead product candidate includes QR-010, a RNA-based oligonucleotide for the treatment of cystic fibrosis. ProQR Therapeutics B.V. is headquartered in Leiden, the Netherlands. “

Other equities analysts also recently issued research reports about the stock. JMP Securities cut their price target on shares of ProQR Therapeutics from $8.00 to $5.00 and set a “market outperform” rating on the stock in a research note on Thursday, April 14th. Raymond James downgraded shares of ProQR Therapeutics from a “strong-buy” rating to a “market perform” rating in a research note on Friday, February 11th. Cantor Fitzgerald cut their price target on shares of ProQR Therapeutics from $6.00 to $3.50 in a research note on Tuesday, April 19th. Stifel Nicolaus downgraded shares of ProQR Therapeutics from a “buy” rating to a “hold” rating and cut their price target for the stock from $20.00 to $3.00 in a research note on Friday, February 11th. Finally, Citigroup lowered shares of ProQR Therapeutics from a “buy” rating to a “hold” rating in a research report on Sunday, February 13th. Five equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $6.59.

Shares of PRQR opened at $0.56 on Thursday. The company has a debt-to-equity ratio of 0.35, a quick ratio of 5.10 and a current ratio of 6.94. The company has a market capitalization of $39.93 million, a price-to-earnings ratio of -0.52 and a beta of 0.97. The company’s 50 day simple moving average is $0.85 and its 200 day simple moving average is $4.29. ProQR Therapeutics has a 1 year low of $0.53 and a 1 year high of $9.09.

ProQR Therapeutics (NASDAQ:PRQRGet Rating) last announced its quarterly earnings data on Thursday, February 24th. The biopharmaceutical company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.26) by ($0.04). The firm had revenue of $0.27 million for the quarter, compared to analysts’ expectations of $0.90 million. ProQR Therapeutics had a negative net margin of 2,469.79% and a negative return on equity of 51.75%. Equities analysts expect that ProQR Therapeutics will post -0.88 EPS for the current fiscal year.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. US Bancorp DE grew its holdings in ProQR Therapeutics by 122.1% during the 3rd quarter. US Bancorp DE now owns 3,693 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 2,030 shares in the last quarter. Daiwa Securities Group Inc. grew its holdings in ProQR Therapeutics by 22.1% during the 4th quarter. Daiwa Securities Group Inc. now owns 13,017 shares of the biopharmaceutical company’s stock valued at $104,000 after purchasing an additional 2,352 shares in the last quarter. Royal Bank of Canada grew its holdings in ProQR Therapeutics by 5.4% during the 3rd quarter. Royal Bank of Canada now owns 58,273 shares of the biopharmaceutical company’s stock valued at $488,000 after purchasing an additional 3,000 shares in the last quarter. Northern Trust Corp acquired a new stake in ProQR Therapeutics during the 4th quarter valued at $51,000. Finally, Dorsey Wright & Associates acquired a new stake in ProQR Therapeutics during the 4th quarter valued at $55,000.

About ProQR Therapeutics (Get Rating)

ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It is primarily developing sepofarsen that is in phase II/III illuminate trial for treating leber's congenital amaurosis 10 disease; QR-421a, which is in phase I/II stellar trial for usher syndrome type 2 and non-syndromic retinitis pigmentosa; QR-1123 that is in phase I/II aurora trial for the treatment of autosomal dominant retinitis pigmentosa; and QR-504a, which is in first clinical trial for the treatment of fuchs endothelial corneal dystrophy.

Read More

Get a free copy of the Zacks research report on ProQR Therapeutics (PRQR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for ProQR Therapeutics (NASDAQ:PRQR)

Receive News & Ratings for ProQR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.